An interventional study of Instagram-Based Breast Cancer Education and Website-Based Breast Cancer Education in Breast Cancer, sponsored by Gümüşhane Universıty. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Gümüşhane Universıty · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 396 studies in Breast Neoplasms with a site in Turkey — 81 open to participants now, 127 under way, 46 of them phase 3. Breast Neoplasms · Turkey.
Among the 396 studies in Breast Neoplasms with a site in Turkey, this one is the 146th largest by enrollment of the 318 interventional ones that give a count, is one of 41 that started in 2022, is one of 181 with no phase, and was the 391st registered.
14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →81 of the 396 studies in Breast Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:
Bursa City Hospital · Sites in Turkey
Ages 18–85 · Women only
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Sites in Turkey
Ages 18–65 · Women only
Ege University · Sites in Turkey
Ages 18+ · Women only
Mucahide Emine Fidancı Kuas · Sites in Turkey
Ages 18–85 · Women only · Healthy volunteers
Ferit Yetik · Sites in Turkey
Ages 18–75 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 20 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
396 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 36 · Phase 3 98 · Phase 4 5
First in 1996; this study’s year is marked. 41 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 103 across the 318 interventional studies, 84 across the 78 observational. Of the 245 that completed or were terminated, 67 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
131 of 396 have an industry lead sponsor. The 10 most frequent:
Gümüşhane Universıty is the lead sponsor of 34 studies on the registry; 5 are open to participants now.
Gümüşhane Universıty has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
30 of the studies in Breast Neoplasms with a site in Turkey that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
Add all 30 to your calendar (.ics) → With an account.
Among the 396 studies in Breast Neoplasms with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized study compared three ways of delivering standardized digital education about breast cancer and early detection among adult women. Participants were assigned to education through a private social media account, a dedicated website, an electronic brochure delivered through WhatsApp, or a control group. The study assessed whether the educational formats changed breast cancer screening beliefs and prevention behaviors after 12 weeks.
A total of 120 women were allocated equally to four parallel groups (30 per group) using a computer-generated block randomization sequence. The three intervention groups received the same core breast cancer and early-detection information adapted to Instagram, a website, or an electronic brochure, together with weekly platform-specific reminders for 12 weeks. The control group received no active digital education during the study period. Outcomes were measured at baseline and after 12 weeks using the Breast Cancer Screening Beliefs Scale and the Scale of Factors Affecting Women's Breast Cancer Prevention Behaviors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants accessed interactive posts, stories, and short videos through a private Instagram account and received weekly reminders for 12 weeks.
Behavioral: Instagram-Based Breast Cancer Education
Participants accessed a dedicated website containing standardized breast cancer and screening information and received weekly reminders for 12 weeks.
Behavioral: Website-Based Breast Cancer Education
Participants received a standardized electronic brochure through WhatsApp and weekly reminders for 12 weeks.
Behavioral: E-Brochure Breast Cancer Education
Participants received no active digital education during the 12-week study period.
Standardized breast cancer and early-detection education delivered through interactive posts, stories, and short videos on a private Instagram account, with weekly reminders for 12 weeks.
Standardized breast cancer and early-detection education delivered through a dedicated website, with weekly reminders for 12 weeks.
Standardized breast cancer and early-detection education delivered as an electronic brochure through WhatsApp, with weekly reminders for 12 weeks.
Change From Baseline in Breast Cancer Screening Beliefs Scale Total Score
The Breast Cancer Screening Beliefs Scale measures attitudes toward health screening, knowledge and perceptions of breast cancer, and perceived barriers to mammography. The outcome is the change in total score from baseline to post-intervention; higher scores indicate more favorable screening beliefs.
Time frame: Baseline and 12 weeks
Change From Baseline in Women's Breast Cancer Prevention Behaviors Scale Total Score
The Scale of Factors Affecting Women's Breast Cancer Prevention Behaviors assesses support systems, self-efficacy, self-care, stress management, motivation, information seeking, and attitude. The outcome is the change in total score from baseline to post-intervention; higher scores indicate more favorable prevention behaviors.
Time frame: Baseline and 12 weeks
Change From Baseline in BCSB and WBCPB Subscale Scores
Changes in the Breast Cancer Screening Beliefs Scale subscales (attitudes toward health screening, knowledge and perceptions of breast cancer, and barriers to mammography) and the Women's Breast Cancer Prevention Behaviors Scale subscales (support systems, self-efficacy, self-care, stress management, motivation, information seeking, and attitude).
Time frame: Baseline and 12 weeks
Plan to share: Yes — De-identified individual participant data underlying the results reported in the publication may be shared.
Time frame: Beginning after publication and available upon reasonable request; no predetermined end date.
Access criteria: Researchers with a scientifically sound proposal may request access from the corresponding author. Data will be shared after review of the request and subject to applicable ethical and confidentiality requirements.
No publications or documents are linked to this record.
Ran from Jun 2022 to primary completion in Dec 2022, 6 months.
Of 2,663 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 6 months is below that.
Counting every sponsor, half of 2,773 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gümüşhane Universıty